Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.
Brain tumor immune cells show unexpected activation patterns in patients, suggesting personalized immunotherapies tailored to actual patient biology may outperform standard approaches.
This NPJ Precision Oncology review from the Massachusetts General Hospital Brain Tumor Immunology Program examines the distinct immunobiology of GBM TILs — highlighting that patient tumors harbor clonally expanded granzyme K+ T cells rather than the exhausted phenotypes seen in murine glioma models — and explores translational implications for immunotherapy. Emerging TCR-based approaches including adoptive TIL transfer, neoantigen vaccines, and engineered receptor strategies are evaluated as potential paths toward more rational, personalized GBM immunotherapy.
What the study was
- Study design
- review
- Population
- Glioblastoma (GBM) patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
NPJ Precision Oncology publication from Harvard/MGH on GBM immunotherapy — one of the most challenging cancers with no standard-of-care immunotherapy; highlights translational gap between murine models and human tumors; corrected from HIGH to STANDARD: score 7 with no HIGH-forcing flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.